Related Experiment Video
Updated: Jul 12, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Biologic effectiveness increases with earlier biologic initiation after severe asthma onset.
Arjun Mohan1, Reynold A Panettieri2, Wendy C Moore3
1Department of Medicine, Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich.
The Journal of Allergy and Clinical Immunology. Global
|July 11, 2026
Summary
Starting biologic treatment sooner for severe asthma improves its effectiveness. A shorter delay from severe asthma onset to biologic initiation is linked to fewer exacerbations and better outcomes.
Area of Science:
- Pulmonology
- Immunology
- Clinical Medicine
Background:
- Severe asthma can lead to irreversible airway damage through fibrosis and remodeling.
- Chronic inflammation is a key driver of these pathological changes in the airways.
Purpose of the Study:
- To evaluate how the time between severe asthma onset and biologic treatment initiation affects treatment effectiveness.
- To analyze outcomes in US adults with severe asthma treated by specialists.
Main Methods:
- The CHRONICLE observational study (NCT03373045) compared exacerbation rates before and after biologic initiation.
- Multivariable models identified factors independently associated with exacerbation rates during treatment.
Main Results:
- A 59% reduction in exacerbation rates was observed post-biologic initiation.
- Shorter time to biologic treatment was independently associated with lower exacerbation rates (rate coefficient = 1.04; P < .001).
- Black race was also associated with higher exacerbation rates (rate ratio = 2.40; P = .009).
Conclusions:
- Earlier initiation of biologic therapy in severe asthma is associated with improved treatment effectiveness.
- Adjusting for prior exacerbations and race, a shorter delay to treatment correlates with reduced exacerbations.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:29Asthma-I: Introduction
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...